|
|
2310 Alfred-Nobel Boulevard
Montreal, Quebec H4S 2B4 Canada
phone:(514) 336-7800
fax:(514) 336-7242
|
|
| Symbol |
TH-T |
| Exchange |
TSX |
| Founded |
0 |
| Employees |
70 |
|
|
| www.theratech.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Technology company engaged in the discovery and development of therapeutic products in the fields of endocrinology and metabolism. |
|
| Management |
| Yves Rosconi, L. Pharm., MBA, President and Chief Executive Officer; Luc Tanguay, M.Sc., CFA, Senior Executive Vice President and Chief Financial Officer; Marie-No?l Colussi, CA, Vice President, Finance; Chantal Desrochers, B. Ph., MBA, Vice President, Business Development and Commercialization; Andrea Gilpin, Ph.D., MBA, Vice President, Investor Relations & Communications |
| |
|
|
|
|
|
|
| Recent Results |
| Company partners include ALZA Corporation (United States), Bachem (Switzerland), Johnson & Johnson Pharmaceutical Research & Development, LLC (United States) and Sakai Chemical (Japan). Theratechnologies holds equity positions in the following spinoff companies; Celmed BioSciences (61.6%), Andromed (24.8%) and Ecopia Biosciences (6.0%). |
| |
|
|
|
|
| Keywords |
| tesamorelin, abdominal fat, lipodystrophy, serono, therapeutic |
|
|
|
| Description |
|
Theratechnologies is a Canadian technology company engaged in the discovery and development of therapeutic products in the fields of endocrinology and metabolism. The company has and is developing a portfolio of peptides at various stages of development for the treatment of catabolic and metabolic disorders, as well as osteoporosis and type II diabetes. |
|
| Products / Services |
The Company currently holds three major products targeting multi-billion dollar markets: The first stabilized peptide developed by Theratechnologies over the last years is ThGRF (TH9507), a growth hormone-releasing factor analogue for which scientific results have shown potential in a variety of catabolic and metabolic indications. ThPTH or parathormone is a hormone which has the ability to promote bone formation, potentially reducing by a significant margin the incidence of fractures in people suffering from osteoporosis. ThGLP-1 or glucagon-like peptide-1 could be one of the most promising emerging therapy for type II diabetes since the discovery of insulin. Theratechnologies also owns a rich portfolio of peptides derived from the LAP (Long Acting Peptide) and ExoPep technologies.
|
|
| Technology / Differentiation |
| The company's current development programs target growth hormone replacement, osteoporosis and diabetes. The most advanced of these is ThGRF, a stabilized analogue of a natural peptide known as growth hormone-releasing factor. ThPTH is a transdermal formulation of parathyroid hormone for the treatment of osteoporosis and ThGLP-1 is a stabilized analogue of GLP-1, a multi-active hormone for diabetes. |
|
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
